Mylan Inc. (MYL) announced that its privately held Indian subsidiary, Matrix Laboratories Ltd., has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Lansoprazole Delayed-release Capsules, 15 mg and 30 mg. Lansoprazole Delayed-release Capsules are the generic version of Tap Pharmaceuticals' proton pump inhibitor Prevacid DR Capsules.
The company said the product is shipping immediately and will be sold under the Mylan Pharmaceuticals brand.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.